A new study by thoracic surgeons and pathologists at Memorial Sloan Kettering Cancer Center shows that a specific pattern found in the tumor pathology of some lung cancer patients is a strong predictor of recurrence.
The combination of the immunotherapy drug ipilimumab and the investigational antibody drug nivolumab led to long-lasting tumor shrinkage in more than half of patients with metastatic melanoma, according to results from a Phase I trial simultaneously published in The New England Journal of Medicine and presented at the 49th Annual Meeting of the American Society of Clinical Oncology.
The experimental drug selumetinib is the first targeted therapy to demonstrate significant clinical benefit for patients with metastatic uveal melanoma, according to new Memorial Sloan Kettering Cancer Center research presented at the 49th annual meeting of the American Society of Clinical Oncology.
Foundation Medicine and Memorial Sloan Kettering Cancer Center today announced a partnership that brings together clinical, genomic and computational expertise to advance patient care in hematologic cancers.
Endometrial tumors can be reclassified into distinct subtypes based partly on their genomic makeup and may respond to targeted drugs already being tested in clinical trials, according to a large-scale genomic analysis led by researchers at Memorial Sloan Kettering Cancer Center and other centers within The Cancer Genome Atlas Research Network.
Scientists from Memorial Sloan Kettering Cancer Center and Eureka Therapeutics have collaborated to create the new human monoclonal antibody, which targets a protein associated with many types of cancer and is of great interest to cancer researchers.
Memorial Sloan Kettering Cancer Center announces the appointments of medical oncologist Anas Younes, surgical pathologist David S. Kimstra, surgeon Julio Garcia-Aguilar, and radiologist Wolfgang Weber.
The experimental drug selumetinib may allow some patients with advanced thyroid cancer to overcome resistance to radioiodine (RAI), the most effective therapy for the disease, according to new research from Memorial Sloan Kettering Cancer Center.